Logo image
A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells
Journal article   Open access   Peer reviewed

A high-throughput screen identifies that CDK7 activates glucose consumption in lung cancer cells

Chiara Ghezzi, Alicia Wong, Bao Ying Chen, Bernard Ribalet, Robert Damoiseaux and Peter M Clark
Nature communications, v 10(1), pp 5444-15
29 Nov 2019
PMID: 31784510
url
https://www.nature.com/articles/s41467-019-13334-8.pdfView
Published, Version of Record (VoR) Open
url
https://doi.org/10.1038/s41467-019-13334-8View
Published, Version of Record (VoR) Open

Abstract

A549 Cells Carcinoma, Non-Small-Cell Lung - metabolism Cell Line, Tumor Class I Phosphatidylinositol 3-Kinases - drug effects Class I Phosphatidylinositol 3-Kinases - metabolism Cyclin-Dependent Kinases - antagonists & inhibitors Cyclin-Dependent Kinases - metabolism Glucose - metabolism Glucose Transporter Type 1 - drug effects Glucose Transporter Type 1 - metabolism High-Throughput Screening Assays Humans Lung Neoplasms - metabolism Phenylenediamines - pharmacology Phosphorylation Protein Kinase Inhibitors - pharmacology Pyrazoles - pharmacology Pyrimidines - pharmacology Quinazolines - pharmacology RNA Polymerase II - drug effects RNA Polymerase II - genetics RNA Polymerase II - metabolism RNA, Messenger - metabolism Signal Transduction Triazines - pharmacology
Elevated glucose consumption is fundamental to cancer, but selectively targeting this pathway is challenging. We develop a high-throughput assay for measuring glucose consumption and use it to screen non-small-cell lung cancer cell lines against bioactive small molecules. We identify Milciclib that blocks glucose consumption in H460 and H1975, but not in HCC827 or A549 cells, by decreasing SLC2A1 (GLUT1) mRNA and protein levels and by inhibiting glucose transport. Milciclib blocks glucose consumption by targeting cyclin-dependent kinase 7 (CDK7) similar to other CDK7 inhibitors including THZ1 and LDC4297. Enhanced PIK3CA signaling leads to CDK7 phosphorylation, which promotes RNA Polymerase II phosphorylation and transcription. Milciclib, THZ1, and LDC4297 lead to a reduction in RNA Polymerase II phosphorylation on the SLC2A1 promoter. These data indicate that our high-throughput assay can identify compounds that regulate glucose consumption and that CDK7 is a key regulator of glucose consumption in cells with an activated PI3K pathway.

Metrics

15 Record Views
28 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Biochemistry & Molecular Biology
Logo image